Organic compounds -- part of the class 532-570 series – Organic compounds – Cyclopentanohydrophenanthrene ring system containing
Reexamination Certificate
2007-12-04
2007-12-04
Badio, Barbara P. (Department: 1617)
Organic compounds -- part of the class 532-570 series
Organic compounds
Cyclopentanohydrophenanthrene ring system containing
C552S519000
Reexamination Certificate
active
11138105
ABSTRACT:
Compounds, compositions and methods for treating degenerative diseases and disorders are disclosed, the compounds having the following structure (I):including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1and R2are as defined herein.
REFERENCES:
patent: 4897389 (1990-01-01), Aroonsakul
patent: 5486511 (1996-01-01), Weintraub et al.
patent: 5512557 (1996-04-01), Collins
patent: 5521168 (1996-05-01), Clark
patent: 5554601 (1996-09-01), Simpkins et al.
patent: 5554603 (1996-09-01), Kim et al.
patent: 5723455 (1998-03-01), Tanabe et al.
patent: 5824672 (1998-10-01), Simpkins et al.
patent: 5843934 (1998-12-01), Simpkins
patent: 5859001 (1999-01-01), Simpkins et al.
patent: 5866561 (1999-02-01), Ungs
patent: 5877169 (1999-03-01), Simpkins
patent: 5939407 (1999-08-01), Landfield
patent: 5972923 (1999-10-01), Simpkins et al.
patent: 5990078 (1999-11-01), Toran-Allerand
patent: 5990177 (1999-11-01), Brown
patent: 6036973 (2000-03-01), Guittard et al.
patent: 6089941 (2000-07-01), Glickman et al.
patent: 6140067 (2000-10-01), Anderson et al.
patent: 6172056 (2001-01-01), Droescher et al.
patent: 6172088 (2001-01-01), Simpkins et al.
patent: 6197833 (2001-03-01), Simpkins et al.
patent: 6207658 (2001-03-01), Simpkins et al.
patent: 6232326 (2001-05-01), Nelson
patent: 6251863 (2001-06-01), Yue
patent: 6258856 (2001-07-01), Chamberlain et al.
patent: 6274603 (2001-08-01), Poirier
patent: 6319914 (2001-11-01), Simpkins et al.
patent: 6326365 (2001-12-01), Simpkins et al.
patent: 6333317 (2001-12-01), Lee et al.
patent: 6334998 (2002-01-01), Uckun et al.
patent: 6339078 (2002-01-01), Simpkins et al.
patent: 6350739 (2002-02-01), Simpkins et al.
patent: 6420353 (2002-07-01), Lathe et al.
patent: 6432643 (2002-08-01), Einstein et al.
patent: 6511969 (2003-01-01), Hermsmeyer
patent: 6566064 (2003-05-01), Shiraki et al.
patent: 6605605 (2003-08-01), Hammerly
patent: 6677324 (2004-01-01), Knauthe et al.
patent: 6692763 (2004-02-01), Cummings et al.
patent: 6844456 (2005-01-01), Covey
patent: 6958327 (2005-10-01), Hillisch et al.
patent: 2001/0051602 (2001-12-01), Poirier
patent: 2002/0022593 (2002-02-01), Yue
patent: 2002/0028793 (2002-03-01), Wassermann
patent: 2002/0035100 (2002-03-01), Prokai et al.
patent: 2002/0102725 (2002-08-01), Zabarovsky et al.
patent: 2002/0132802 (2002-09-01), Covey
patent: 2002/0165213 (2002-11-01), Weiss et al.
patent: 2002/0183299 (2002-12-01), Voskuhl
patent: 2003/0045510 (2003-03-01), Schloss et al.
patent: 2003/0049838 (2003-03-01), Thompson et al.
patent: 2003/0050295 (2003-03-01), Pang
patent: 2003/0119796 (2003-06-01), Strony
patent: 2003/0129134 (2003-07-01), Chenard et al.
patent: 2003/0130303 (2003-07-01), Coe et al.
patent: 2003/0176409 (2003-09-01), Offner
patent: 2003/0186954 (2003-10-01), Hermsmeyer
patent: 2004/0043410 (2004-03-01), Carnazza
patent: 2004/0067923 (2004-04-01), Elger et al.
patent: 2004/0223963 (2004-11-01), Cheung et al.
patent: 2004/0259886 (2004-12-01), Day et al.
patent: 2005/0031651 (2005-02-01), Gervais et al.
patent: 0 753 300 (1997-01-01), None
patent: WO 01/10430 (2001-02-01), None
patent: WO 02/13870 (2002-02-01), None
patent: WO 02/36605 (2002-05-01), None
patent: WO 03/015704 (2003-02-01), None
patent: WO 03/072109 (2003-09-01), None
patent: WO 03/072110 (2003-09-01), None
Peters et al., J. Med. Chem., vol. 32, No. 7, pp. 1642-1652, 1989.
Chemical Abstract Service, Accession No. 1992:235946, 1992.
El-Khawass, S., et al., “Steroidal Derivatives. Part 2. Synthesis and Endocrinologic Properties of Novel Acylhydrazone Derivatives of Steroids,”Pharmazie, 35(3):143-145, 1980.
Liu, R., et al., “Neuroprotective Effects of a Novel Non-receptor-binding Estrogen Analogue: In Vitro and in Vivo Analysis,”Stroke, 33(10):2485-91, Oct. 2002.
Peters, R., et al., “17-Desoxy Estrogen Analogues,”J Med Chem., 32(7):1642-52, Jul. 1989.
Xia, S., et al., “The Estrogen Receptor is Not Essential for All Estrogen Neuroprotection: New Evidence from a New Analog,”Neurobiol Dis., 9(3):282-93, Apr. 2002.
Badeau, M., et al., “Estrogen A-ring Structure and Antioxidative Effect on Lipoproteins,”J Steroid Biochem Mol Biol., 96(3-4):271-8, Aug. 2005.
Behl, C., et al., “17-beta Estradiol Protects Neurons from Oxidative Stress-induced Cell Death in Vitro,”Biochem Biophys Res Commun., 216(2):473-82, Nov. 13, 1995.
Behl, C., et al., “Neuroprotection Against Oxidative Stress by Estrogens: Structure-activity Relationship,”Mol Pharmacol., 51(4):535-41, Apr. 1997.
Betts, J., et al., Neuropathological Aspects of Mitochondrial DNA Disease,Neurochem Res., 29(3):505-11, Mar. 2004.
Buzdar, A., TAS-108: A Novel Steroidal Antiestrogen,Clin Cancer Res., 11(2 Pt 2):906s-8s, Jan. 15, 2005.
Conrad, K., et al., “Emerging Role of Relaxin in Renal and Cardiovascular Function,”Am J Physiol Regul Integr Comp Physiol., 287(2):R250-61, Aug. 2004.
Deshpande, S., “Protective Role of Estrogen in the Neurodegenerative Disorder,”Indian J Physiol Pharmacol., 44(1):43-9, Jan. 2000.
Doggrell, S., “Experimental and Clinical Studies Show That the Probucol Derivative AGI-1067 Prevents Vascular Growth,”Expert Opin Investig Drugs., 12(11):1855-9, Nov. 2003.
Du, D-M., et al Development of bivalent acetylcholinesterase inhibitors as potential therapeutic drugs for Alzheimer's disease,Curr Pharm Des., 10(25):3141-56, 2004.
Dykens, J., et al., “Polycyclic Phenols, Estrogens and Neuroprotection: A Proposed Mitochondrial Mechanism,”Exp Gerontol., 38(1-2):101-7, Jan.-Feb. 2003.
Eng-Wong, J., et al., “Raloxifene and Its Role in Breast Cancer Prevention,”Expert Rev Anticancer Ther., 4(4):523-32, Aug. 2004.
Finsterer, J., “Mitochondriopathies,”Eur J Neurol., 11(3):163-86, Mar. 2004.
Garcia-Segura, L., et al., “Neuroprotection by estradiol,”Prog Neurobiol., 63(1):29-60, Jan. 2001.
Gradishar, W., “Tamoxifen—what Next?,”Oncologist, 9(4):378-84, 2004.
Hayes, E., “Biology of Primate Relaxin: A Paracrine Signal in Early Pregnancy,”Reprod Biol Endocrinol., 2:36, Jun. 16, 2004.
Kompoliti, K., “Estrogen and Parkinson's Disease,”Front Biosci., 8:s391-400, May 1, 2003.
Kulkarni, J., et al., “A Clinical Trial of Adjunctive Oestrogen Treatment in Women with Schizophrenia,”Arch Women Ment Health., 5(3):99-104, Nov. 2002.
Kupina, N., et al., “Cytoskeletal Protein Degradation and Neurodegeneration Evolves Differently in Males and Females Following Experimental Head Injury,”Exp Neurol., 180(1):55-73, Mar. 2003.
Leibelt, D., et al., “Evaluation of Chronic Dietary Exposure to Indole-3-carbinol and Absorption-enhanced 3,3′-diindolylmethane in Sprague-dawley Rats,”Toxicol Sci., 74(1):10-21, Jul. 2003.
Lord, R., et al., “Estrogen Metabolism and the Diet-cancer Connection: Rationale for Assessing the Ratio of Urinary Hydroxylated Estrogen Metabolites,”Altern Med Rev.7(2):112-29, Apr. 2002.
McCullough, L., et al., “Estrogen and Ischemic Neuroprotection: An Integrated View,”Trends Endocrinol Metab., 14(5):228-35, Jul. 2003.
McDonnell, D., “The Molecular Pharmacology of Estrogen Receptor Modulators: Implications for the Treatment of Breast Cancer,”Clin Cancer Res., 11(2 Pt 2):871s-7s, Jan. 15, 2005.
Montagna, P., et al., “MELAS Syndrome: Characteristic Migrainous and Epileptic Features and Maternal Transmission,”Neurology, 38(5):751-4, May 1998.
Mooradian, A., “Antioxidant Properties of Steroids,”J Steroid Biochem Mol Biol., 45(6):509-11, Jun. 1993.
Moosmann, B., et al. “The Antioxidant Neuroprotective Effects of Estrogens and Phenolic Compounds are Independent from Their Estrogenic Properties,”PNAS, 96:8867-8872, Aug. 1999.
Nikov, G., et al., “Interactions of Synthetic Estrogens with Human Estrogen Receptors,”J. Endocrinol., 170:137-145, 2001.
Pavlakis, S., et al., “Mitochondrial Myopathy, Encephalopathy
Badio Barbara P.
Migenix Corp.
LandOfFree
Compounds and methods for cytoprotection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for cytoprotection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for cytoprotection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3830946